Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 4, 2010, Pages 420-427

  Henrich, Timothy J ^a,b   Tsibris, Athe M N ^b,c   Lewine, Nicolas R P ^d   Konstantinidis, Ioannis ^d   Leopold, Kay E ^d   Sagar, Manish ^a,b   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

antiviral therapy; CCR5 antagonists; HIV 1; HIV 1 resistance; maraviroc; TAK 779; vicriviroc

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN GP 120; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; VICRIVIROC;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT;

AMIDES; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PIPERAZINES; PYRIMIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; TRIAZOLES;

EID: 78650236401     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f25574     Document Type: Article

References (43)

1. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med. 2007;58:445-459.
2. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
3. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196:304-312.
4. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008;198:1113-1122.
5. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:4911-4919.
6. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial Agents Chemother. 2005;49:4721-4732.
7. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS. 2007;21:1293-1299.
8. Ketas TJ, Kuhmann SE, Palmer A, et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology. 2007;364:281-290.
9. Ketas TJ, DiPippo VA, Lam E, et al. PRO 140, a humanized CCR5 monoclonal antibody, is active against genotypically diverse and enfuvirtide-resistant strains of HIV-1. Abstract WEPEA093. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2007; Sydney, Australia.
10. Lalezari J, Yadavalli GK, Para M, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis. 2008; 197:721-727.
11. Murga JD, Franti M, Pevear DC, et al. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents Chemother. 2006; 50:3289-3296.
12. Hartley O, Gaertner H, Wilken J, et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA. 2004;101:16460-16465.
13. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol. 2004;78:2790-2807.
14. Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology. 2005;338:182-199.
15. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology. 2008;373:387-399.
16. Tsibris AM, Sagar M, Gulick RM, et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol. 2008;82:8210-8214.
17. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359-2371.
18. Antiviral Drugs Advisory Committee (AVDAC) Briefing Document. Maraviroc Tablets NDA 22-128. 2007: 104. Available at: www.fda.gov/OHRMS/ DOCKETS/AC/07/briefing/2007-4283b1-01-Pfizer.pdf. Accessed July 1, 2010.
19. Yusa K, Maeda Y, Fujioka A, et al. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem. 2005;280:30083-30090.
20. Ogert RA, Ba L, Hou Y, et al. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol. 2009;83:12151-12163.
21. Watson C, Jenkinson S, Kazmierski W, et al. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol. 2005;67:1268-1282.
22. Pugach P, Ketas TJ, Michael E, et al. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology. 2008;377:401-407.
23. Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology. 2007;361:212-228.
24. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA. 2002;99:395-400.
25. Berro R, Sanders RW, Lu M, et al. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009;5:e1000548.
26. Ogert RA, Hou Y, Ba L, et al. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology. 2010. E-pub ahead of print.
27. Colonno R, Rose R, McLaren C, et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004; 189:1802-1810.
28. Demeter LM, Meehan PM, Morse G, et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:136-144.
29. Dueweke TJ, Pushkarskaya T, Poppe SM, et al. A mutation in reverse transcriptase of bis (heteroaryl) piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleo-side inhibitors. Proc Natl Acad Sci USA. 1993;90:4713-4717.
30. Gong YF, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother. 2000;44:2319-2326.
31. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998;72:986-993.
32. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905.
33. Cocchi F, DeVico AL, Garzino-Demo A, et al. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med. 1996;2:1244-1247.
34. Tsibris AM, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PloS One. 2009;4:e5683.
35. Etemad B, Fellows A, Kwambana B, et al. Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol. 2009;83:9694-9708.
36. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol. 1992;66:2232-2239.
37. Sagar M, Wu X, Lee S, et al. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol. 2006;80:9586-9598.
38. Jansson M, Popovic M, Karlsson A, et al. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA. 1996;93:15382-15387.
39. Koning FA, Kwa D, Boeser-Nunnink B, et al. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis. 2003;188:864-872.
40. Repits J, Oberg M, Esbjornsson J, et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol. 2005;86:2859-2869.
41. Felsovalyi K, Nadas A, Zolla-Pazner S, et al. Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C. AIDS Res Hum Retroviruses. 2006;22:703-708.
42. Patel MB, Hoffman NG, Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol. 2008;82:903-916.
43. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol. 2008;73:789-800.